ISSUE 2 : FEBRUARY 2019

The Veeda Newsletter

MERGER & ACQUISITION

Advair generics and acquisitions to hit GSK in 2019

This is part of a root-and-branch renewal across the business, with a vision of a pharma-focused, oncology and immunology led company emerging.
Read more : https://www.pmlive.com/pharma_news/advair_generics_and_acquisitions_to_hit_gsk_in_2019_1277511

Aurobindo acquires Apotex's businesses in 5 European countries

Aurobindo Pharma on Monday said it had completed the acquisition of Canadian generic pharma firm Apotex’s commercial operations and certain supporting infrastructure in five European countries.
Read more : https://www.thehindu.com/business/Industry/aurobindo-pharma/article26238747.ece

Samsung Bioepis inks biosimilar deals to enter China

C-Bridge will establish a new company, AffaMed Therapeutics, under terms of the deal, and will license multiple biosimilar candidates from Samsung Bioepis to commercialize in China.
Read more : https://bioprocessintl.com/bioprocess-insider/global-markets/samsung-bioepis-inks-biosimilar-deals-to-enter-china/


Cipla acquires Wellthy stake to bring digital therapeutics to India

Drugmaker Cipla is to acquire an 11.7% stake in digital therapeutics company Wellthy Therapeutics.
Read more : https://www.thepharmaletter.com/article/cipla-acquires-wellthy-stake-to-bring-digital-therapeutics-to-india


5 Top Drug/Biotech Merger & Acquisition Targets for 2019

As far as M&A activity in the biotech/drug sector is concerned, 2018 started with a bang with expectations of record breaking activity in the year. The new tax reforms left more cash in the hands of drug/biotech companies that could be invested for M&A activity.
Read more : https://www.zacks.com/stock/news/342034/5-top-drugbiotech-merger-amp-acquisition-targets-for-2019

www.veedacr.com
info@veedacr.com
Contact Us